Biotech News

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Aprea Therapeutics (APRE)Aprea Therapeutics2026-06-25 13:46 ESTClinical readout

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea’s

Open original release

Related news

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

View all latest news

Aprea Therapeutics

Aprea Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States